Journals / Türk Onkoloji Dergisi / 2019 / Cilt: 34 - Sayı: 2

Prognostic Role of Family History in Patients with Triple Negative Breast Cancer

Pages
87–91
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In addition, there was no difference between patients with andwithout family history (breast and ovarian cancer) in terms of local control, disease-free, and overallsurvival (respectively p=0.13, p=0.11, p=0.59).

📌 3 Key Takeaways

🎯
Objective & Hypothesis:OBJECTIVEBreast cancer is divided into four subtypes according to the receptor type.
📊
Key Findings & Data:Patients with all three of theER, PR, and c-erb2 receptors negative constitute 20% of all breast cancer cases.
💡
Conclusion & Impact:In addition, there was no difference between patients with andwithout family history (breast and ovarian cancer) in terms of local control, disease-free, and overallsurvival (respectively p=0.13, p=0.11, p=0.59).
🔬Design:Review & Systematic Survey
📍Scope:2017 Verileri
⚙️Variables:Domain Parameters

Abstract

OBJECTIVEBreast cancer is divided into four subtypes according to the receptor type. Patients with all three of theER, PR, and c-erb2 receptors negative constitute 20% of all breast cancer cases. Cases of this group,called triple negative (TN), progress more aggressively than other subtypes. Additionally, familial transmission is more frequent in these patients. Therefore, we planned this study to investigate whether thefamily history was prognostic on survival in patients with TN breast cancer (TNBC).METHODSA total of 158 patients who were diagnosed with TNBC between 1996 and 2017 were retrospectivelyreviewed. Patients’ age, family history, stage, grade, type of surgery, clinical follow-up, adjuvant, andneoadjuvant treatments of the tumor according to TNM system, and their effects on general and disease-free survival were analyzed.RESULTSThe median age was 46 years (range 24–82). The mean follow-up period was 72 months (range 10–224).A total of 64 (41%) patients had family risk for cancers (other than breast and ovarian). A total of 57(36%) patients had breast cancer history in their family, 11 (7%) had ovarian cancer history in their family, and 4 (3%) had history of both cancers in their family. There was no significant difference betweentumor characteristics and family history. In addition, there was no difference between patients with andwithout family history (breast and ovarian cancer) in terms of local control, disease-free, and overallsurvival (respectively p=0.13, p=0.11, p=0.59). The only statistically significant outcome was that diagnosis of a second primary cancer in the opposite breast for no family history group was 2% compared to14% for those with family histories (p=0.03).CONCLUSIONThe family history of breast cancer did not affect the prognosis of the patient independently of the degree ofconsanguinity. These patients should be carefully monitored for the second primary of the opposite breast.

🔖

Cite This Article

ALTINOK, A., MÜSLÜMANOĞLU, M. (2022). Prognostic Role of Family History in Patients with Triple Negative Breast Cancer. Türk Onkoloji Dergisi, Cilt: 34 - Sayı: 2, 87–91. https://ajindex.com/articles/639234

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature 2000;406(6797):747–52
  2. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006;295(21):2492–502
  3. Rakha EA, El-Rehim DA, Paish C, Green AR, Lee AH, Robertson JF, et al. Basal phenotype identifies a poor prognostic subgroup of breast cancer of clinical importance. Eur J Cancer 2006;42(18):3149–56
  4. Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007;13(8):2329–34
  5. Boyle P. Triple-negative breast cancer: epidemiological considerations and recommendations. Ann Oncol 2012;23 Suppl 6:vi7–12
  6. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007;13(15 Pt 1):4429–34
  7. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003;100(14):8418–23
  8. Lakhani SR, Reis-Filho JS, Fulford L, Penault-Llorca F, van der Vijver M, Parry S, et al; Breast Cancer Linkage Consortium. Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res 2005;11(14):5175–80
  9. Bidard FC, Conforti R, Boulet T, Michiels S, Delaloge S, André F. Does triple-negative phenotype accurately identify basal-like tumour? An immunohistochemical analysis based on 143 'triple-negative' breast cancers. Ann Oncol 2007;18(7):1285–6. 10.Kennedy RD, Quinn JE, Johnston PG, Harkin DP. BRCA1: mechanisms of inactivation and implications for management of patients. Lancet 2002;360(9338):1007–14
  10. Lin NU, Vanderplas A, Hughes ME, Theriault RL, Edge SB, Wong YN, et al. Clinicopathologic features, patterns of recurrence, and survival among women with triplenegative breast cancer in the National Comprehensive Cancer Network. Cancer 2012;118(22):5463–72. 12.Xie Y, Gou Q, Wang Q, Zhong X, Zheng H. The role of BRCA status on prognosis in patients with triple-negative breast cancer. Oncotarget 2017;8(50):87151–62. 13.Silverstein MJ, Skinner KA, Lomis TJ. Predicting axillary nodal positivity in 2282 patients with breast carcinoma. World J Surg 2001;25(6):767–72.